Vimta Labs liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
16.47×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.43×3.43×2.92×2.90×2.87×
2.97×2.97×2.53×2.44×2.47×
52.525.015.812.129.6
189159123102106
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIMTALABS₹519.80

Vimta Labs Limited

· Pharma & Health
₹ CrorePeersSUVENTAKEMcap ₹2,322 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————16.47
Current Ratio2.872.902.923.433.43
Quick Ratio2.472.442.532.972.97
Cash, Equiv & ST Investments29.612.115.825.052.5
Working Capital106.0101.9123.4159.3188.9
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.